TARA is trading 7.7% down at $3.84 following the announced resignation of its Chief Medical Officer, effective June 26, 2026.
- The leadership change introduces uncertainty regarding clinical strategy and execution, which is a critical concern for a small biotech firm.
- The decline reflects profit-taking following last week’s gains and increased investor caution despite relatively calm broader markets.